MetaCap

Crescent Biopharma (CBIO) vs Geron (GERN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Crescent Biopharma (CBIO) has outperformed Geron (GERN) over the past year, losing 0.5% versus a loss of 22.3%. Over five years, GERN leads with a -40.8% price change compared with -92.7% for CBIO. Geron is the larger company by market cap ($560.9 million vs $543.2 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CBIO-0.46%GERN-22.26%
+113%+38%-38%
Nov 21, 20251 yearNov 20, 2026
CBIO-93.09%GERN-43.46%
+232%+60%-111%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CBIO versus GERN key metrics
MetricCBIOGERN
Share price$13.00$0.8707
Market cap$543.21M$560.94M
1-day change+0.70%-4.63%
YTD return+9.61%-34.04%
1-year return-0.46%-22.26%
5-year return-92.74%-40.77%
Forward P/E—9.67
EPS (TTM)$-7.29$-0.08
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$10.84M—
Net income (latest FY)$-153.94M$-83.50M
Operating margin-1407.52%—
Net margin-1419.61%—
52-week high$27.41$2.01
52-week low$8.72$0.84
Distance from 52-week high-52.57%-56.68%
Analyst consensusstrong_buybuy
Avg. price target upside+148.69%+301.98%
Average volume361.17K13.05M
Shares outstanding38.90M644.24M
Employees80258
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CBIO has outperformed GERN by 21.8 percentage points over the past year.

About Crescent Biopharma

CBIO stock →

Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003.

Health Care · Biotechnology: Pharmaceutical Preparations · 80 employees

About Geron

GERN stock →

Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML.

Health Care · Biotechnology: Pharmaceutical Preparations · 258 employees

CBIO vs GERN FAQ

Which is bigger, Crescent Biopharma or Geron?

Geron (GERN) is larger, with a market capitalization of $560.94M compared with $543.21M for Crescent Biopharma (CBIO).

Which stock has performed better over the past year, CBIO or GERN?

CBIO returned -0.46% over the past 12 months, compared with -22.26% for GERN (price return, excluding dividends). Past performance does not predict future results.

Are Crescent Biopharma and Geron in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons